Recent Quotes (30 days)

You have no recent quotes
chg | %

Aralez Pharmaceuticals Inc  

(Public, TSE:ARZ)   Watch this stock  
Find more results for ARZ
2.23
-0.08 (-3.46%)
Apr 27 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 2.18 - 2.36
52 week 2.00 - 8.75
Open 2.35
Vol / Avg. 11,125.00/65,639.00
Mkt cap 115.67M
P/E     -
Div/yield     -
EPS -1.71
Shares 65.68M
Beta     -
Inst. own 46%
May 9, 2017
Q1 2017 Aralez Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
May 3, 2017
Aralez Pharmaceuticals Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
May 3, 2017
Aralez Pharmaceuticals Inc Extraordinary Shareholders Meeting - 9:00AM EDT - Add to calendar
Mar 13, 2017
Q4 2016 Aralez Pharmaceuticals Inc Earnings Release
Mar 13, 2017
Q4 2016 Aralez Pharmaceuticals Inc Earnings Call - Webcast
Feb 22, 2017
Aralez Pharmaceuticals Inc at RBC Capital Markets Healthcare Conference
  

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -155.53% -189.75%
Operating margin -140.98% -189.03%
EBITD margin - -157.08%
Return on average assets -31.29% -37.47%
Return on average equity -92.44% -153.39%
Employees 105 -
CDP Score - -

Address

7100 West Credit Ave Suite 101
MISSISSAUGA, ON L5N 0E4
Canada
+1-905-8761118 (Phone)
+1-905-5674618 (Fax)

Website links

Description

Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).

Officers and directors

Arthur S. Kirsch Independent Chairman of the Board
Age: 63
Andrew I. Koven President, Chief Business Officer
Age: 57
Adrian Adams Chief Executive Officer, Director
Age: 64
Scott J. Charles Chief Financial Officer, Senior Vice President
Age: 41
Jennifer Lou Armstrong Executive Vice President - Human Resources and Administration
Age: 45
Eric L. Trachtenberg Chief Compliance Officer, General Counsel, Corporate Secretary
Age: 42
Mark A. Glickman Chief Commercial Officer
Age: 50
James Patrick Tursi M.D. Chief Medical Officer
Age: 51
Kenneth B. Lee Jr. Lead Independent Director
Jason M. Aryeh Independent Director
Age: 48